Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis
Osteoporosis drugs show no clear heart risk or benefit
This narrative review evaluates the cardiovascular safety profile of anti-osteoporosis therapies including bisphosphonates, denosumab, and r…
Common osteoporosis drugs don't have a clear effect on heart health, but one newer drug still raises safety questions.
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma. The authors synthesize current know…
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
Bisphosphonates reduce vertebral fracture risk in multiple myeloma, spinal cord compression effect unclear
Can bone drugs protect the spine in multiple myeloma? A new review weighs in.
A meta-analysis of 11 randomized trials in adults with multiple myeloma found bisphosphonates reduced vertebral fracture risk compared to no…
Bone drugs called bisphosphonates lower the risk of spine fractures in multiple myeloma patients, though evidence on preventing spinal cord …